Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: J Neurol

Search In Journal Title:

Abbravation: Journal of Neurology

Search In Journal Abbravation:

Publisher

Springer Berlin Heidelberg

Search In Publisher:

DOI

10.1002/jcla.10089

Search In DOI:

ISSN

1432-1459

Search In ISSN:
Search In Title Of Papers:

Patientreported adverse effects of highdose intr

Authors: Peter Joseph Jongen Ioanna Stavrakaki Bernard Voet Erwin Hoogervorst Erik van Munster Wim H Linssen Ludovicus G Sinnige Wim I Verhagen Leo H Visser Ruud van der Kruijk Freek Verheul Jan Boringa Marco Heerings Werner Gladdines Fredrik Lönnqvist Pieter Gaillard
Publish Date: 2016/06/07
Volume: 263, Issue: 8, Pages: 1641-1651
PDF Link

Abstract

In a prospective multicenter observational study we evaluated the frequency severity and impact on activities of daily living ADL of adverse effects AEs of highdose intravenous methylprednisolone IVMP in relapsing remitting multiple sclerosis MS patients with a relapse Online selfreport questionnaires stating IVMP’s most common AEs were completed at baseline the 2nd day of treatment and 1 day and 1 week after treatment Eightyfive patients were included 66 completed the baseline questionnaire and 59 completed at least one postbaseline questionnaire Patients reported on average 4 median AEs two 34  reported no AE Most frequent was change in taste 61  facial flushing 61  sick/stomach pain 53  sleep disturbance 44  appetite change 37  agitation 36  and behavioral changes 36  Of all AEs 343  were severe and 379  impacted on ADL A 3day course resulted in 4 median AEs and a 5day course in 7 All patients with high disease impact had two or more AEs compared with 79  of those with low impact p  001 Of patients with high disability 45  had severe AEs compared with 16  of those with low disability Severe central nervous system CNSrelated AEs occurred two times more frequently in patients with high disease impact and twoandahalf times more frequently in patients with high disability Therefore in virtually all patients highdose IVMP leads to AEs with about one of three AEs being severe with impact on ADL Patients with high disease impact or high disability may experience more severe AEs due to a higher occurrence of severe CNSrelated AEsMultiple sclerosis MS is a chronic disease of the central nervous system CNS in which immunemediated inflammation and degeneration lead to loss of myelin and axons In four out of five patients the disease course is initially characterized by relapses and remissions relapsingremitting MS RRMS 1 Most patients fully recover after a relapse but this can take weeks or months 2 Treatment with highdose methylprednisolone shortens the relapse duration and increases the chances of recovery 3 A European Federation of Neurological Societies task force recommends treatment with intravenous iv or oral methylprednisolone in a dose of at least 500 mg daily for 5 days or iv methylprednisolone IVMP 1 g daily for 3 days 3Methylprednisolone like other corticosteroids is associated with a number of adverse effects AEs affecting the skin skeleton muscles eyes CNS electrolytes metabolism and the endocrine cardiovascular immune and gastrointestinal systems often in a dosedependent manner 4 In the USA in 2004 corticosteroids were the most common specific cause for drugrelated AEs accounting for 103  of all drugrelated AEs and 141000 hospital stays 5 Although most serious AEs are related to the longterm oral use shortterm steroidinduced symptoms are frequent especially with highdose treatment needed to treat relapses 6Patientreported outcomes PROs receive growing attention in drug research PROs are measurements of any aspect of a patient’s health status that comes directly from the patient and can be used to evaluate how a treatment affects patients’ functioning and wellbeing 7 Studies using PROs to evaluate the AEs of longterm oral corticosteroid treatment showed that patients experience an average of 21–23 treatmentrelated symptoms 8 9Most studies on IVMP treatment in MS did not focus on AEs 10 11 Despite their frequent occurrence the severity of IVMP’s AEs is thought to be minor as they seldom require hospitalization or medical interventions However from a patient perspective this may be questioned as studies of corticosteroids in general show that they may bother patients and affect the quality of life 9 In patients with immune thrombocytopenic purpura AEs of corticosteroids were found to be more bothersome from the patients’ perspectives than from the doctors’ perspectives 9 Moreover in MS patients the distress from CNSrelated AEs like mood change behavioral change and sleep disturbance may add to the burden of MSrelated CNS symptomsIn view of the above we performed the patientreported adverse effects of methylprednisolone for relapse treatment in multiple sclerosis FEEL study We specifically assessed from a patient perspective the occurrence severity bothering and impact of AEs during and after highdose IVMP treatment of an MS relapse We hypothesized that more severe AEs would be reported by patients treated with a 5day course than by those treated with a 3day course and by patients who had not been treated with IVMP in recent years due to them being less acquainted with IVMP’s AEs We also expected that CNSrelated AEs would be more frequent and more severe in patients with high disease impact and high disability as we thought it likely that patients with more MSrelated CNS dysfunction might be especially susceptible to severe AEs affecting the CNS


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Toothbrushing-induced seizures at onset of cryptogenic partial epilepsy: a case report
  2. Associated and predictive factors of depressive symptoms in patients with Parkinson’s disease
  3. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy
  4. Walter Rudolf Hess (1881–1973)
  5. Current concepts and future approaches to vestibular rehabilitation
  6. Clinical features associated with REM sleep behavior disorder symptoms in the early stages of Parkinson’s disease
  7. Vestibular animal models: contributions to understanding physiology and disease
  8. Primary leptomeningeal lymphoma of the cauda equina: a rare cause of radiculopathy
  9. DWI and FLAIR imaging in herpes simplex encephalitis: a comparative and topographical analysis
  10. Interferon beta in secondary progressive multiple sclerosis
  11. Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity
  12. Diaphragm of the internal carotid artery: a novel cause of pulsatile tinnitus
  13. Retinal nerve fiber layer thickness in subgroups of multiple sclerosis, measured by optical coherence tomography and scanning laser polarimetry
  14. Tolvaptan treatment of severe stroke-like symptoms and bilateral subcortical diffusion restriction due to syndrome of inappropriate secretion of ADH after polytrauma
  15. Tolvaptan treatment of severe stroke-like symptoms and bilateral subcortical diffusion restriction due to syndrome of inappropriate secretion of ADH after polytrauma
  16. Detailing intra-lesional venous lumen shrinking in multiple sclerosis investigated by sFLAIR MRI at 7-T
  17. Neurological complications of Behçet’s syndrome
  18. Highly skewed inactivation of the wild-type X-chromosome in asymptomatic female carriers of spinal and bulbar muscular atrophy (Kennedy’s disease)
  19. Meningitis–retention syndrome
  20. APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score
  21. Early MRI findings in Creutzfeldt-Jakob disease
  22. Causes and characteristics of horizontal positional nystagmus
  23. The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson’s disease
  24. Mastication-induced vertigo and nystagmus
  25. Need for extensive diagnostic work-up for patients with lacunar stroke
  26. Low testosterone and myasthenia gravis in males: a national record-linkage study
  27. Plasma levels of nitric oxide and stroke outcome
  28. High field MR imaging and 1 H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis
  29. Cesare Vigna (1819–1892)
  30. Cesare Vigna (1819–1892)
  31. Aquaporin-4 seropositivity in a patient with coeliac disease but normal neurological examination and imaging
  32. Repetitive magnetic stimulation A novel therapeutic approach for myofascial pain syndrome
  33. Downbeat positioning nystagmus is a common clinical feature despite variable phenotypes in an FHM1 family
  34. Psychological interventions for migraine: a systematic review
  35. Respiratory dysfunction in Charcot–Marie–Tooth disease type 1A
  36. Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation
  37. Epiretinal membrane: a treatable cause of visual disability in myotonic dystrophy type 1
  38. Spinocerebellar ataxia type 17 in a patient from an Indian kindred
  39. ‘Switching off’ SUNCT by sudden head movement: a new symptom
  40. A clinical, radiological and outcome study of status epilepticus from India
  41. The impact of subthalamic deep brain stimulation on caregivers of Parkinson’s disease patients: an exploratory study
  42. Management of respiratory symptoms in ALS
  43. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease
  44. Opsoclonus–myoclonus–ataxia syndrome and HIV seroconversion
  45. Vascular risk factors are associated with faster decline of Alzheimer disease: a longitudinal SPECT study
  46. Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci
  47. Presenilin 2 mutation R71W in an Italian early-onset sporadic Alzheimer’s disease case
  48. Recovery from mild traumatic brain injury
  49. Modafinil for Parkinson’s disease fatigue
  50. Diagnosis and treatment of upper limb apraxia
  51. Familial aggregation in atypical Parkinson’s disease: a case control study in multiple system atrophy and progressive supranuclear palsy
  52. Thymectomy: role in the treatment of myasthenia gravis
  53. Long-term EMG recordings differentiate between parkinsonian and essential tremor
  54. Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies
  55. Cortical thinning in drug-naive Parkinson’s disease patients with depression
  56. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease
  57. Frontal lobe function and behavioral changes in amyotrophic lateral sclerosis: a study from Southwest China
  58. Tic disorders: from pathophysiology to treatment
  59. Parkinson’s disease: news on tremor, subthalamic stimulation and impulse control disorders
  60. The use of multiattribute decision models in evaluating triptan treatment options in migraine
  61. Psychiatric disorders in idiopathic-isolated focal dystonia
  62. Domain-specific versus generalized cognitive screening in acute stroke
  63. Multiple sclerosis imaging: recent advances
  64. Hemifacial presentation of mitochondrial myopathy
  65. Teleneurology in stroke management: costs of service in different organizational models
  66. Small-fibre neuropathy related to bulbar and spinal-onset in patients with ALS
  67. Cerebral blood flow abnormalities in patients with neurally mediated syncope
  68. Specific electron transport chain abnormalities in amyotrophic lateral sclerosis
  69. Parkinson’s disease-related disorders in the impulsive-compulsive spectrum
  70. Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients’ perspectives
  71. Bladder dysfunction in subacute combined degeneration
  72. Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis
  73. Missense exchanges in the TTBK2 gene mutated in SCA11
  74. Diffusion tensor imaging reveals widespread white matter abnormalities in children and adolescents with myotonic dystrophy type 1
  75. Prior medical conditions and the risk of amyotrophic lateral sclerosis
  76. An epidemiological study of neuromyelitis optica in Cuba
  77. Brachial neuritis caused by varicella-zoster diagnosed by changes in brachial plexus on MRI
  78. Subthalamic nucleus stimulation in Parkinson’s disease
  79. Dopaminergic medication does not improve stepping responses following backward and forward balance perturbations in patients with Parkinson’s disease
  80. Novel EXOSC3 mutation causes complicated hereditary spastic paraplegia
  81. A genome wide linkage disequilibrium screen in Parkinson’s disease
  82. Differential effect of Huntington's and Parkinson's diseases in programming motor sequences of varied lengths
  83. Accuracy of subjective and objective handwriting assessment for differentiating Parkinson’s disease from tremulous subjects without evidence of dopaminergic deficits (SWEDDs): an FP-CIT-validated study
  84. The utility of F wave chronodispersion in lumbosacral radiculopathy
  85. Accuracy of subjective and objective handwriting assessment for differentiating Parkinson’s disease from tremulous subjects without evidence of dopaminergic deficits (SWEDDs): an FP-CIT-validated study
  86. Recurrent rhabdomyolysis due to muscle β-enolase deficiency: very rare or underestimated?
  87. Progressive ascending myelopathy: atypical forms of multiple sclerosis or what else?
  88. Paroxysmal raised intracranial pressure associated with spinal meningeal cysts
  89. The relationship between impairment of voluntary movements and cognitive impairment in Huntington’s disease
  90. Long-term domain-specific improvement following poor grade aneurysmal subarachnoid hemorrhage

Search Result: